1. Home
  2. FT vs ACIU Comparison

FT vs ACIU Comparison

Compare FT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Universal Trust

FT

Franklin Universal Trust

HOLD

Current Price

$7.84

Market Cap

199.8M

Sector

Finance

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

N/A

Current Price

$2.56

Market Cap

221.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FT
ACIU
Founded
1988
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.8M
221.9M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
FT
ACIU
Price
$7.84
$2.56
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
34.3K
157.2K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
7.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$706.75
Revenue Next Year
N/A
$321.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.79
$2.03
52 Week High
$8.35
$4.00

Technical Indicators

Market Signals
Indicator
FT
ACIU
Relative Strength Index (RSI) 36.60 63.05
Support Level $7.84 $2.51
Resistance Level $8.08 $2.66
Average True Range (ATR) 0.06 0.13
MACD -0.01 0.03
Stochastic Oscillator 13.33 87.96

Price Performance

Historical Comparison
FT
ACIU

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: